Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan L Kelly

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Nature Communications|April 15, 2018
Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritisAlessandro Angelini, Yoshishige Miyabe, Daniel Newsted, et al.
Mabs|June 6, 2015
High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in miceRyan L Kelly, Tingwan Sun, Tushar Jain, et al.
Scientific Reports|September 17, 2020
An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTANishant Mehta, Sainiteesh Maddineni, Ryan L Kelly, et al.
Cell Reports|December 8, 2016
Temporally Programmed CD8α<sup>+</sup> DC Activation Enhances Combination Cancer ImmunotherapyAlice Tzeng, Monique J Kauke, Eric F Zhu, et al.
Plos One|August 23, 2012
A novel highly potent therapeutic antibody neutralizes multiple human chemokines and mimics viral immune modulationMichelle L Scalley-Kim, Bruce W Hess, Ryan L Kelly, et al.
Nature Medicine|November 8, 2016
Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responsesKelly D Moynihan, Cary F Opel, Gregory L Szeto, et al.
Nature|November 27, 2025
Author Correction: Inhibiting membrane rupture with NINJ1 antibodies limits tissue injuryNobuhiko Kayagaki, Irma B Stowe, Kamela Alegre, et al.
Nature|May 17, 2023
Inhibiting membrane rupture with NINJ1 antibodies limits tissue injuryNobuhiko Kayagaki, Irma B Stowe, Kamela Alegre, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Nature Communications|April 15, 2018
Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritisAlessandro Angelini, Yoshishige Miyabe, Daniel Newsted, et al.
Mabs|June 6, 2015
High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in miceRyan L Kelly, Tingwan Sun, Tushar Jain, et al.
Scientific Reports|September 17, 2020
An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTANishant Mehta, Sainiteesh Maddineni, Ryan L Kelly, et al.
Cell Reports|December 8, 2016
Temporally Programmed CD8α<sup>+</sup> DC Activation Enhances Combination Cancer ImmunotherapyAlice Tzeng, Monique J Kauke, Eric F Zhu, et al.
Plos One|August 23, 2012
A novel highly potent therapeutic antibody neutralizes multiple human chemokines and mimics viral immune modulationMichelle L Scalley-Kim, Bruce W Hess, Ryan L Kelly, et al.
Nature Medicine|November 8, 2016
Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responsesKelly D Moynihan, Cary F Opel, Gregory L Szeto, et al.
Nature|November 27, 2025
Author Correction: Inhibiting membrane rupture with NINJ1 antibodies limits tissue injuryNobuhiko Kayagaki, Irma B Stowe, Kamela Alegre, et al.
Nature|May 17, 2023
Inhibiting membrane rupture with NINJ1 antibodies limits tissue injuryNobuhiko Kayagaki, Irma B Stowe, Kamela Alegre, et al.
Pageof 2